Lim, Jonathan <br/><br/>
Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA.  [electronic resource] 

 -  Future oncology (London, England)  May 2019 
 - 1493-1504 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1744-8301 
<br/><br/><label>Standard No.: </label>10.2217/fon-2019-0052  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Afatinib--therapeutic use<br/>Aged<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride--therapeutic use<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Middle Aged<br/>Mutation<br/>Prognosis<br/>Protein Kinase Inhibitors--therapeutic use<br/>Retrospective Studies<br/>Survival Rate<br/>Time Factors<br/>Young Adult